Century Therapeutics (NASDAQ:IPSC) Announces Quarterly Earnings Results

Century Therapeutics (NASDAQ:IPSC) issued its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01, FiscalAI reports.

Century Therapeutics Stock Down 6.3%

Shares of NASDAQ IPSC traded down $0.11 on Thursday, hitting $1.63. The company had a trading volume of 608,756 shares, compared to its average volume of 1,004,740. The firm has a market capitalization of $295.14 million, a P/E ratio of -1.75 and a beta of 1.78. Century Therapeutics has a 12-month low of $0.43 and a 12-month high of $3.04. The business has a 50 day moving average of $1.65 and a two-hundred day moving average of $2.07.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on IPSC shares. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research note on Tuesday, September 29th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Century Therapeutics presently has an average rating of “Hold” and an average target price of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.